Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA is a single-arm, phase II study evaluating effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Matulonis, Ursula A., Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150846/
https://www.ncbi.nlm.nih.gov/pubmed/36716407
http://dx.doi.org/10.1200/JCO.22.01900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150846/
https://www.ncbi.nlm.nih.gov/pubmed/36716407
http://dx.doi.org/10.1200/JCO.22.01900

Ejemplares similares